Oncology PracticeFDA expands indication for ribociclib for advanced breast cancerJuly 18, 2018Breast CancerMetastatic Breast Cancer
Oncology PracticeABP 980 similar to trastuzumab in HER2+ breast cancer in all but nameJuly 10, 2018Breast Cancer
Oncology PracticeHigher BMI tied to lower breast cancer risk in women before menopauseJune 22, 2018Breast CancerPatient & Survivor Care
The Journal of Community and Supportive OncologyASCO 2018: Less is more as ‘tailoring’ takes on new meaningJune 21, 2018Breast CancerLung CancerGenitourinary Cancer
The Journal of Community and Supportive OncologyThe long-term effects of posttreatment exercise on pain in young women with breast cancerJune 21, 2018Breast CancerPatient & Survivor Care
Oncology PracticeRural cancer patients report faster care than urban counterpartsJune 18, 2018Patient & Survivor CarePractice ManagementBreast CancerLung CancerGastroenterologyGenitourinary CancerBusiness of Medicine
Oncology PracticeEverolimus/exemestane improves PFS of ER+/HER2– breast cancer vs. everolimus aloneJune 8, 2018Breast Cancer
Oncology PracticeTAILORx marks major advance for precision medicine in breast cancerJune 6, 2018Breast Cancer
Oncology PracticeDr. William J. Gradishar shares breast cancer take-aways from ASCO 2018June 5, 2018Breast Cancer
Oncology PracticeIMPACT study: Matched targeted therapy improves survival in advanced cancerJune 4, 2018MelanomaGastroenterologyBreast CancerLung CancerGastrointestinal Cancer
Hospital Physician: Hematology/OncologyHER2-Positive Breast Cancer: Current ManagementJune 4, 2018Breast Cancer
Oncology PracticePI3K inhibitor/fulvestrant has modest benefit, serious toxicity in breast cancerJune 3, 2018Breast Cancer
Oncology PracticeTAILORx: Most women with intermediate risk ER+ breast cancer can safely skip chemoJune 3, 2018Breast Cancer
